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Patient 1. A 19-year-old male was referred for evaluation of a
glomerulopathy. Frequency of micturition had been noted when he was
2.5 years old, and urinalysis at that time revealed microscopic hema-
tuna (25 to 50 red blood cells/high-power field) and hyaline and granular
casts. Excretory urography was normal. Annual evaluations revealed
persistent microscopic hematuria and 24-hour protein excretion of 80 to
150 mg. Hearing tests were normal at 5 years, but over the next 2 years
a sensorineural hearing loss was detected and was treated with a
hearing aid, which the patient continues to wear.
At age 13 years, microscopic hematuria again was noted. The 24-hour
urinary protein was 536 mg and creatinine clearance was 162 mI/mini
1.73 m2. Proteinuria persisted after the patient had been lying down for
an extended period. Percutaneous renal biopsy was performed. Light
microscopy revealed diffuse interstitial scarring with foci of tubular
atrophy. The interstitial scarring did not contain significant interstitial
infiltrate, although focal accumulations of lymphocytes were present.
The tubules showed foci of foamy changes within the tubular epithe-
hum. The glomeruli displayed varying degrees of sclerosis with lobular
accentuation and an increase in mesangial matrix. Occasional glomeruli
were globally sclerotic; others were segmentally sclerotic. Immunoflu-
orescence studies disclosed variable focal mesangial and peripheral
granular 1gM accompanied by focal C3 deposition. Electron micros-
copy revealed irregular thickening of the glomerular basement mem-
brane (GBM) alternating with areas of attenuation. The thickened areas
of basement membrane showed marked lamination with inclusion of
granular dense particles. Based on the histology, a diagnosis of hered-
Presentation of this Forum is made possible by grants from Pfizer,
Incorporated; Sandoz, Incorporated; Marion Merrell Dow, Incorpo-
rated; Merck Sharp & Dohme International; Amgen, Incorporated; and
Dialysis Clinic, Incorporated.
© 1992 by the International Society of Nephrology
itary nephritis was made, specifically, Alport's syndrome with a mod-
erate degree of chronicity.
Ophthalmologic evaluation revealed anterior lenticonus and white
punctate opacities in the periphery of the retina. Audiologic examina-
tion revealed severe bilateral sensorineural deafness. Laboratory find-
ings were BUN, 18 mg/dl; sodium, 139 mmohiliter; potassium, 3.8
mmol/liter; chloride, 103 mmol/liter; bicarbonate, 28 mmol/hiter; total
protein, 5.4 giliter; albumin, 3.0 g/liter; cholesterol, 296 mg/dl; uric acid,
7.6 mg/dl; creatinine, 1.0 nig/dI; alkaline phosphatase, 126 lU/liter; and
creatinine clearance, 106 mI/mm. The 24-hour urinary protein excretion
was 5662 mg.
The patient's 16-year-old brother had no signs of renal disease or
deafness (Fig. I). His 52-year-old father was healthy, and no renal
disease was apparent on the paternal side of the family. The maternal
grandfather was well. The maternal grandmother was known to have
Addison's disease and hyperthyroidism but no renal abnormalities. The
patient's mother was healthy at age 41 but had had microscopic
hematuria during pregnancy and on two other occasions. Her hearing
was normal.
Patient 2. A 19-year-old male was referred for genetic counseling. He
had been well until the age of 9, when he became inattentive at school
and was found to have bilateral sensorineural hearing loss. Two years
later he consulted his family doctor because of recurrent sore throats;
urine dipstick testing revealed occult hematuna and 3 + proteinuria.
The creatinine clearance was 107 mI/mm, and the 24-hour urinary
protein excretion was 210 mg. Microscopic hematuria was noted
repeatedly throughout the next 10 years. A diagnosis of Alport's
syndrome was made in light of the family history, but renal biopsy was
not performed.
The patient's father had been well until the age of 22, when routine
medical evaluation disclosed microscopic hematuria and proteinuria
(Fig. 2). Over the next 10 years, progressive sensorineural deafness was
documented and was attributed to occupational exposure to heavy
machinery. At the age of 35, he was hypertensive (160/110 mm Hg) and
was treated with various antihypertensive agents. His creatinine clear-
ance is 78 mI/mm at age 41.
The proband's younger sister was asymptomatic at age 17. As a child
she had had recurrent urinary tract infections; retrograde pyelography
and excretory urography were normal. Evaluation had disclosed micro-
scopic hematuria, and proteinuria was detected on dipstick testing. At
age 15, she had a creatinine clearance of 117 mllmin/l .73 m2. Urinalysis
revealed 30 to 100 red blood cells/high-power field; multiple hyaline,
granular, and red cell casts; and pyuria on two occasions. A 24-hour
urine sample contained 420 mg of protein. Audiologic testing revealed
mild bilateral sensorineural deafness. The proband's elder brother was
healthy, and urinalysis revealed no abnormality. The paternal grand-
mother had died at age 71, apparently of colon cancer. The paternal
grandfather had died at age 49 and was believed to have been hyper-
tensive and to have had more than one myocardial infarction. The sole
paternal aunt was known to have had hematuna, proteinuria, and 'mild
kidney failure." She had died as a result of complications of surgery for
breast cancer. Her son became noticeably deaf at the age of 15;
currently, at age 26, he wears a hearing aid. Microscopic hematuria had
been noted repeatedly during his teens, and Alport's syndrome had
been diagnosed on the basis of clinical evaluation. The proband's
mother and maternal grandparents were healthy and had no history
suggestive of hereditary nephritis.
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Discussion
DR. STEPHEN REEDERS (Associate Professor, Departments
of Internal Medicine and Genetics, Yale University School of
Medicine, New Haven, Connecticut): Most cases of Alport's
syndrome are X-linked; that is, the mutation occurs in a gene on
the X chromosome. Figure 3 shows part of one of the classic
Alport's syndrome pedigrees, kindred P [1], which is very
clearly X-linked: males are the ones predominantly affected,
and all of them eventually develop end-stage renal disease
(ESRD). Females, when affected, almost always have hema-
tuna but tend to have mild renal impairment (although ESRD
does occasionally occur) and tend not to have hearing loss.
None of these features, however, is diagnostic of X-linked
disease. What is diagnostic of X-linkage in such a large pedigree
is the absence of a single case of male-to-male transmission. A
male receives his X chromosome from his mother, so male-to-
male transmission of a disease is incompatible with a mutation
on the X chromosome.
In clinical settings it is often difficult to determine the mode of
inheritance from the family history. The first pedigree presented
here contains a male with clinical and histologic features of
Alport's syndrome (Fig. 1). His mother has some mild features
of the disease, in this case hematuria, but the evidence is
insufficient to confirm that she is a carrier of an Alport' s
syndrome mutation. In this family, the disease is at least
compatible with X-linkage because there is no male-to-male
transmission. Whereas male-to-male transmission excludes
X-linkage, failure to observe it in a small family is not diagnostic
because too few opportunities might have presented themselves
for it to occur.
On an a priori basis, the disease in the first pedigree is very
likely to be X-linked because family studies have found this
form of Alport's syndrome to predominate [2—6]. In Utah for
example, a study of a large number of families suggests that
about 85% of pedigrees are convincingly X-linked [5, 6]. In
Britain, Flinter et a!, using stringent diagnostic criteria, found
no evidence to suggest the existence of mutations that are not
X-linked [2, 3]. Feingold and colleagues found that 92% of
French families were X-linked [4]. To the extent that these
populations are representative of the family in the first case
report, the prior probability of X-linkage is at least 85%.
The advent of recombinant DNA technology has enabled
demonstration of X-linkage by a second means, co-segregation
(defined as inherited in tandem) of the disease with a DNA
sequence ("genetic marker") that is known to be localized on
the X chromosome. In other words, the disease is inherited
together with a specific X chromosome marker throughout each
family. These techniques have shown Alport's syndrome to be
linked to genetic markers on the long arm of the X chromosome
in many families [3, 5, 7—9]. In fact, X-linkage has been
demonstrated in all families for which data have been pub-
lished. We cannot assume that X-linkage is universal, however,
because published reports of linkage studies frequently lack
conclusive data for X-linked markers and thus suffer from
reporting bias.
Despite the preponderance of evidence in favor of X-chro-
mosome mutations, X-linkage cannot be confidently assumed in
some families with Alport's syndrome. The second case report
provides such an example (Fig. 2). Note that this family
contains a case of male-to-male transmission. Although male-
to-male transmission absolutely excludes an X-linked mutation,
the mode of inheritance can be incorrectly inferred when
phenocopies (that is, phenotypes that mimic the disease but
have a different genetic or molecular basis) are present in the
pedigree. Because Alport's syndrome is a rare disease, the
coincidental presence of phenocopies must be extremely rare.
Nevertheless, it does occur. Indeed, kindred P was originally
thought to have an autosomal mutation [101. Another reason
that could account for apparent (as opposed to true) male-to-
male transmission is that an X-linked mutation is present but
undetected in the mother of the proband. What makes it more
likely that the proband in the second case inherited the disease
from his father is that a paternal aunt also has the disease,
whereas the mother has no family history of nephritis.
Biopsies were not carried out in this family, so one might
argue that this is not a case of Alport's syndrome at all. Setting
semantic issues aside, my opinion is that, in a family in which
glomeruf an hematuria and proteinuria co-segregate with senso-
rineural deafness, the probability that an Alport's-type heredi-
tary nephritis is present is overwhelming.
One of the predictions of autosomal inheritance (the auto-
somes are the 22 numbered chromosomes) is that females
should be affected as often and as severely as males. In the
second family, this is broadly true although the small size of the
family precludes any firm conclusions. At the recent Interna-
tional Workshop on Alport's Syndrome (Oulu, Finland, August
1991), Corinne Antignac (Paris) and David Barker (Salt Lake
Figs. 1 and 2. Upper panel: Family from Patient 1. Lower panel:
Family from Patient 2. The probands are marked with arrows. Affected
individuals are indicated by filled symbols and unaffected individuals by
open symbols. The shaded symbol indicates that the mother of the
proband is a presumed carrier of an Alport's syndrome mutation.
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Fig. 3. Part of Utah kindred P. Filled
symbols indicate affected individuals, open
symbols indicate unaffected individuals, and
hatched symbols indicate obligate
heterozygotes and affected females. "+"
indicates the presence of a PstI site and "—"
the absence of a site in the third exon of the
COL4A5 gene. This PstI site (p*), which is
found only in affected males in kindred P, is
produced by a G — C change that leads to a
Cys — Ser change (bottom panel). The
additional PstI site in affected individuals
produces a 1.9 kb PstI fragment. The wild-
type PstI fragment is 2.2 kb. The nucleotide
sequence of intron 3 is shown in lower case;
the sequence of the 5' end of exon 3 is shown
in upper case. Exons 1, 2, 3 are shown as
hatched bars.
City, Utah) independently presented several families, each
containing at least two cases of male-to-male transmission and
several females with symptomatic forms of the disease. The
pedigrees discussed by Antignac included families previously
reported by Feingold et al, who had concluded that 3 of 37
families they studied had had autosomal mutations [4]. The
numbers of affected males and females were not significantly
different. In Utah kindred K1975, for example, 8 of 14 males
and 3 of 7 females were affected (Barker DF, personal commu-
nication).
In summary, it appears that at least two forms of Alport's
syndrome exist, one caused by X-linked mutations and the
other by autosomal mutations. It is important to determine
whether these forms correlate with particular patterns of clini-
cal expression. Atkin and coworkers, in an extensive popula-
tion-based study in Utah, defined six different phenotypes of
Alport's syndrome [61. Three clinical features were used to
define the phenotypes: onset of ESRD (> 31 yrs, "adult"; < 31
yrs, "juvenile"), presence of deafness, and presence of other
defects. Both the X-linked and autosomal forms of Alport's
syndrome occur with juvenile onset, both are sometimes asso-
ciated with deafness, and both are associated with ocular
abnormalities. Whenever thrombocytopathia is seen, however,
the disease appears to be autosomal [61. Apart from this
observation, which is based on a small number of families, the
mode of inheritance does not correlate with the clinical pattern
of disease. In other words, the autosomal and X-linked muta-
tions apparently cause very similar diseases.
Our assignment here is to shed light on the molecular genetics
of hereditary nephritis. So let's leave the patients and the
pedigrees for a few moments while we examine specifically the
molecular defect in Alport's syndrome. The microscopic abnor-
malities that have been demonstrated in the GBM in patients
with Alport's syndrome [11] suggest that the expressed defect is
in the structural component of the basement membrane. In-
deed, abnormalities in the type IV (basement membrane) col-
lagens have been heavily implicated in the pathogenesis of the
disease. The macromolecular structure of type IV collagen in
basement membrane has been likened to a "chicken-wire"
meshwork (Fig. 4). We now know of at least five type IV
collagen isoforms in GBM: al(IV), a2(IV), a3(IV), a4(IV), and
a5(IV). The primary structure of all the chains is similar (Fig.
4). Although the fine details have been worked out only for
al (IV) and a2(IV), which are the abundant "classical" chains
and which were the first to be described, it is likely that the
intermolecular interactions of all 5 types are similar. Each chain
has a non-collagenous (NC 1) domain of approximately 230
residues at the C-terminus, an extensive "collagenous" region
that forms a triple helix with two other chains to form a
protomer, and a 7S, N-terminal, domain. The collagenous
region, which is approximately 1400 residues long, has the
triplet consensus sequence glycine-Xaa-Yaa, where Xaa and
Yaa are non-conserved amino acids, but this arrangement is
interrupted at several points. The interruptions appear to give
flexibility to the protomers. The macromolecular structure is
formed via interactions among the 7S domains of four pro-
tomers [121 and, at the C-terminal end of the molecule, the NCI
domains of two protomers (Fig. 4) [13—15].
Bacterial collagenase releases the NC! domains from other
components of basement membrane as hexamers, each com-
prising three NC1 domains of twQ protomers. The NC1 domains
can be further separated on the basis of molecular weight by
denaturing polyacrylamide gel electrophoresis yielding a series
of monomers (molecular weight: 24,500 to 28,300 kD) and
I '2.2kb —
I 1.9kb +
pP* PIL — I 3'
tttaccag A TOT OCA GTA TOT
Cys Ala Val Cys
tttaccag A TCT GCA GTA TGT
Ser Ala Val Cys
] Wild type —
] Kindred P +
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Fig. 4. The 'chicken-wire" meshwork of type
IV collagen.
dimers (49,000 to 59,000 kD) [16, 17]. These were first fully
characterized by Hudson and colleagues [16, 18—21], who found
monomeric components designated Mia, Mib, M2, and M3 in
bovine tissue. The components Mia and Mib correspond to the
well-characterized abundant species al(IV) and a2(IV),
whereas M2 and M3 are novel chains, designated a3(IV) and
a4(IV). The a5(IV) chain was not detected by protein electro-
phoresis. In the human kidney, the M24, M26, M28+++, and
M28+ fragments separated by 2D-gel electrophoresis corre-
spond to al(IV), a2(IV), a3(IV), and c4(IV), respectively [22].
Before the molecular characterization of the type IV colla-
gens had been achieved, Butkowski and colleagues showed that
one or more of the NC! domains of type IV collagens react with
autoantibody in the sera of patients with Goodpasture's syn-
drome [16, 18]. The link between this observation and Alport's
syndrome was that the characteristic ribbon-like staining of
GBM by Goodpasture's antibodies was absent in many cases of
Alport's syndrome.
Even more striking are the data of Kleppel, who extracted the
GBMs of two patients with Alport's syndrome, electrophoresëd
the monomeric and dimeric NC1 domains, and blotted the
peptides onto membranes [23]. The peptides did not react with
Goodpasture's antibody. Samples from a normal individual and
several other patients with non-Alport renal diseases reacted
normally. Hudson's group has shown that the maximum reac-
tivity of Goodpasture's antibodies is with the 28kD NC1 com-
ponent, which is part of the a3(IV) chain [16—19]. Thus it is
likely that a defect exists in a3(IV) in the GBM of patients with
Alport's syndrome.
These data led to the widely held and reasonable belief that
the molecular defect in Alport's syndrome is produced by a
mutation in the a3(IV) chain of type IV collagen that leads to
the absence of the a3(IV) chain from GBM. This conclusion
persuaded many groups to attempt to isolate the gene encoding
that a3(IV) chain, My colleagues and I were the first to succeed
in this goal [24, 25]. Our cloning strategy was based on the
availability of a short stretch of amino acid sequence [from the
NCI domain of a3(IV)] that had been determined by Hudson's
group. The polymerase chain reaction (PCR) was used to
amplify the DNA encoding the 23-residue segment using prim-
ers corresponding to the ends of the segment. Because most
amino acids can be coded by several different codons, a mixture
of primers corresponding to all possible coding was used. The
68bp product obtained by PCR was used to obtain a cDNA
clone coding for the NC1 domain and part of the collagenous
domain. A human clone also was isolated subsequently [25].
Comparison of the a3(IV) peptide sequence, deduced from the
nucleotide sequence, with the known sequences of the al(IV)
and a2(IV) chains revealed substantial similarities (Fig. 5). The
12 highly conserved cysteine residues that participate in disul-
fide bonding and have been found in every type IV collagen
studied to date, including those from the fruit fly and the worm
Caenorhabditis elegans, were found in the a3(IV) molecule
(Fig. 6). The human 3(IV) NCI domain was found to be 71%
and 60% identical to al(IV) and a2(IV), respectively. Our
finding that synthetic peptides based on the deduced a3(IV)
Nd sequence bind Goodpasture's antibody [26] confirms that
the C-terminus of the a3(IV) chain is the predominant site of
Goodpasture' s epitopes.
In summary, the a3(IV) chain of type IV collagen binds
Goodpasture's antibody and is missing from or undetectable in
the GBMs of many patients with Alport's syndrome. The
obvious question is: is a3(IV) mutated in the disease? Since
most cases of Alport' S syndrome are X-linked, the simplest way
NCI
cefl.g.nou. domain dommin coIIIg.nous domoln
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to resolve the question is to determine whether the 3(IV) gene
maps to the X chromosome. Using a combination of somatic
cell hybrid mapping and in-situ hybridization of an a3(IV) probe
to metaphase chromosomes, we showed that the a3(IV) gene
maps to chromosome 2 [25]. The inescapable conclusion from
this finding is that this gene cannot be the site of X-linked
Alport's syndrome mutations.
Evidence also suggests that immunoreactivity to c4(IV) is
lost in the GBMs of some patients with Alport's syndrome. We
recently cloned the gene for a4(IV) (Fig. 6) and showed that this
gene also maps to chromosome 2 [27]. Thus, it too cannot be the
site of X-linked Alport's syndrome mutations.
Sirkka-Liisa Hostikka, a graduate student studying under the
direction of Karl Tryggvason in Finland, also was working on
this problem and tried to clone the a3(IV) chain and other
"novel" type IV collagens. Her strategy was to use highly
conserved regions common to all type IV collagens as probes.
She made a mixture of oligonucleotide probes corresponding to
all 32 coding possibilities for a 5 amino-acid stretch, Cys-GIn-
Val-Cys-Met, that is highly conserved in type IV collagen.
When a human placenta cDNA library was hybridized with this
mixture, Hostikka found a gene encoding a type IV collagen
whose existence had not been suspected on the basis of
biochemical analysis [28]. The new gene, designated a5(IV),
has all the characteristics of a type IV collagen. Moreover, it
was shown to be present in GBM but not in other renal
basement membranes. The most intriguing observation was that
ct5(IV) maps to the long arm of the X chromosome in the band
q22; this is precisely the region to which X-linked Alport's
syndrome mutations had been mapped by genetic linkage
analysis [3, 5, 7—9]. Therefore, a5(IV) was a strong candidate
for the Alport's syndrome mutation. When Barker et al used a
portion of the a5(IV) cDNA representing the NC! domain to
analyze the PstI-digested genomic DNA from members of
kindred P [1], they found that affected males all have a unique
1.9 kb PstI fragment, whereas normal males all have a 2.2 kb
PstI fragment (Fig. 3). They also noted complete co-segregation
of the 1.9 kb fragment with the disease in this pedigree.
Furthermore, the 1.9 kb fragment has never been seen in a
normal individual. The shorter PstI fragment in affected males
was found to be due to a C-to-G mutation that generates an
additional PstI site and a cysteine-to-serine amino acid change.
The effect of the mutation in kindred P can be explained on
the basis of the known intermolecular disulfide bonds between
the NC1 domains of type IV collagens. Although these bonds
have only been defined for al(IV) and a2(IV), the conservation
of the positions of cysteine residues in all type IV collagens
makes it highly likely that the same rules apply to 5(IV). The
cysteine residue that is mutated in kindred P takes part in one of
the 6 disulfide bonds in the NC1 domain. In basement mem-
brane, of course, the NC! domains are covalent!y linked to
form dimers that are part of the overall collagen superstructure
(Fig. 6a). A Cys-Ser mutation would be expected to disrupt two
of the intermolecular disulfide bonds within each a5(IV) ho-
modimer and one within each heterodimer (Fig. 6b). Current
evidence suggests that homodimerization of a(IV) chains pre-
dominates [29]; if this rule applies to a5(IV), the effect of the
mutation in kindred P would be as shown in Figure 6.
Only one other mutation in a5(IV) collagen has been charac-
terized and reported. In the Utah kindred EP, affected males
have lost exons 5 to 10 of a5(IV) collagen [1]. This deletion is
believed to leave the reading frame intact but leads to the loss
of the C-terminal 193 amino acids of the collagenous domain
and 47 residues of the NC! domain. Presumably the shortened
chain leads to the inability to register the three chains during
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Fig. 6. a The presumed interactions of the NC! domain of two
cr.5(IV) chains. The dimerization is stabilized by intermolecular
disulfide bonds (black bars). Intramolecular disulfide bands are also
shown as black bars. The disulfide bonds are those determined for
the al(IV) chain by Siebold et at [31]. In view of the high degrees of
conservation of all type IV collagens, I have assumed that disulfide
bonds in a5(IV) dimers have the same pattern. The vertical arrows
indicate the collagenous/NCI junctions. b The Cys-Ser mutation in
the có(IV) chain in kindred P (jagged arrow) leads to the loss of an
intermolecular disulfide bond between the NC] domain of a5(IV)
molecules (one indicated by unfilled residues, one by shaded
residues). c In kindred EP a deletion of exons 5—JO of cei(IV) collagen
juxtaposes (vertical arrows) the collagenase domain (black residues)
and the middle of the NC! domain such that a disulfide bridge is
lost.
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Mutation in a5(IV) collagen
Normal synthesis of
a3(lV) and a4QV)
Failure to incorporate
a3(IV) and s4(IV) in
GBM in a stable fashion
Normal synthesis of
a3(IV) and a4(IV)
4
Normal incorporation of
a3(IV) and a4(IV)
into GBM
Mutation in a5(IV)
disrupts a3(IV) and 4(IV)
immunoreactivity
Absence of a3(IV) and a4(IV)
immunoreactivity
Abnormal transcription
or translation of
a3(IV) and a4(IV)
No synthesis of
a3(lV) and a4(IV)
protomer assembly. This is compounded by the loss of one of
the intermolecular disulfide bonds (Fig. 6c).
The discovery of mutations in a5(IV) collagen leaves us with
the task of explaining why antibodies to a3(IV) and a4(IV)
chains fail to react with the GBM of some patients with Alport's
syndrome. At least three hypotheses exist (Fig. 7). The first
entails normal synthesis of the a3(IV) and a4(IV) chains but no
stable incorporation of these chains into GBM. This failure
might occur because the assembly of protomers within the cell
is disturbed or because the aS(IV) mutation is incompatible
with stability of a3(IV)- and a4(IV)-containing protomers in the
extracellular matrix. A second possibility is that a3(IV) and
a4(IV) are synthesized normally and incorporated normally into
the GBM but that the immunoreactivity is blocked by a muta-
tion in a5(IV). The last possibility is that the a5(IV) mutation
affects the transcription or translation of the a3(IV) and a4(IV)
chains. The first of these explanations is strongly favored by the
work of Kieppel et a! [23]. They showed that not only are the
a3(IV) and a4(IV) chains not detectable in situ, but that these
chains cannot be detected by antibodies even when they are
separated from the other GBM components by gel electropho-
resis. Taking all the evidence into account, the most likely
explanation is that some mutations in a5(IV) destabilize the
mature collagen superstructure so that a3(IV) and a4(IV) either
fail to get into the mature superstructure or are removed from it
more rapidly than normal.
Kashtan and colleagues took an antibody (FNS1) to GBM,
produced by a patient with Alport's syndrome who had re-
ceived a renal allograft, and used it to study epidermal base-
ment membrane (EBM) from members of a family with
X-linked Alport's syndrome [301. The EBM of unaffected males
stained normally with the antibody, but the EBM of affected
males did not react. In carrier females, some segments of the
EBM stained, whereas adjacent segments did not. This finding
was ascribed to lyonization, the normal inactivation of all but
one X chromosome in each cell during an early stage of
development. Because inactivation is random, a clone of cells
arising from a common progenitor cell will either carry the
mutant X chromosome or not; the section of EBM produced by
a particular clone will therefore either contain the defect or not.
As a result, the EBM of carrier females is a mosaic. The FNS1
antibody recognizes a collagenase fragment of 26kD, the same
size as the collagenase fragment of aS(IV), but the target of
FNS1 has not been identified as yet. However, at the 1991
International Conference on Alport's Syndrome, Tryggvason
reported that an antibody made by an a5(IV) synthetic peptide
does not react with EBM. It is possible, therefore, that a second
X-linked gene, recognized by FNS1 antibodies, is either indi-
rectly affected by the Alport's syndrome mutation or is mutated
itself.
During the last two years great strides have been made in our
understanding of the molecular basis of hereditary nephritis
with the isolation of the a5(IV) chain and the observation that it
is disrupted in some patients with Alport's syndrome. Several
questions remain unresolved, however. A better understanding
of the structure of basement membrane and the roles of the
different type IV collagen isoforms will be required to explain
the pathophysiology of the disruption of GBM in this disease.
Other lines of investigation will be needed to explain the link
between the molecular defects of the GBM and the progressive
renal failure.
Questions and answers
DR. MICHAEL KASHGARIAN (Professor of Pathology, Yale
University School of Medicine, New Haven, Connecticut):
What is the tissue distribution of a5(IV), and does it correspond
in any way to the clinical manifestations that we see? Is it
present in the lung, eye, or ear?
DR. REEDERS: All the studies of distribution of a5(IV) so far
depend on a polyclonal antibody raised to a synthetic peptide.
Data from Karl Tryggvason, Marie-Claire Gubler, and Mary
Kieppel, presented at the 1991 International Workshop on
Fig. 7. Three possible explanations for the
absence of immunoreactivitv of cd(IV) and
a4(IV) collagen chains in X-linked Alport's
syndrome.
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Alport's Syndrome, indicate that a5(IV) is found in GBM but
virtually nowhere else in the kidney. It also is found in the
retina and in the anterior lens membrane. I know of no studies
on the ear. There is staining in the lung but it is not clear-cut.
The choroid plexus is positive. The epidermal basement mem-
brane is negative but, according to Tryggvason, there is some
staining of the stroma of the skin. Most other tissues don't
contain a5(IV). The answer to your question is that the distri-
bution of a5(IV) is entirely compatible with the sites of pathol-
ogy in Alport's syndrome.
DR. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York, Stony Brook, New York): Yet there are
patients with classic X-linked Alport's syndrome who do not
have hearing loss.
DR. REEDERS: That's true, but it is conceivable that different
mutations produce different phenotypes. So one might not
always find pathology at all the sites at which a gene is
expressed. The traditional understanding of genetics includes
dominant and recessive diseases, but the study of genetics at
the molecular level entails much more complicated genotype!
phenotype associations. Some mutations might affect both
tissues, whereas others might affect only the GBM. One can
imagine a situation in which a particular mutation disrupts the
GBM in the kidney but has little effect in the ear because, for
example, the macromolecular structure of type IV collagen
might be different in the two tissues, even if the structure does
contain some of the same components. Another possible expla-
nation is that the patient does not develop a particular manifes-
tation unless coincidental environmental or genetic influences
are present. The coincidental factors might be different for
manifestations in each organ. Perhaps genetic variation in
a3(IV) or a4(IV) affects the expression of the disease. We will
need to know more about what a5(IV) does before we can
explain the effects of different mutations in different organs.
DR. DAVID ELLISON (Associate Professor of Medicine, Yale
University School of Medicine): Is it known whether the
absence of staining of the GBM by anti-GBM antibodies is
present throughout development, and whether the GBM stains
when renal function is still normal in patients with Alport's
syndrome? Or does the abnormality develop only after the renal
disease develops?
DR. REEDERS: When tissue has been available from early
specimens, a proportion fails to stain with Goodpasture's
antibody. I don't believe that fetal tissue has been available,
however.
DR. ELLISON: How then does that jibe with the observation
that the kidneys develop normally in these patients? Why
doesn't the disease occur at birth or in utero? Why does it only
occur later?
DR. REEDERS: That's a very good question, These mutations
are present from conception throughout the life of the individ-
ual. Tryggvason has shown that a5(IV) is expressed in fetal
kidney (Tryggavason K, personal communication). Presum-
ably, the molecule has a role in fetal kidney. Yet some affected
individuals don't develop serious problems for many, many
years; that's one of the mysteries of this disease. The finding of
a simple mutation in the a5(IV) chain of type IV collagen
doesn't automatically explain hematuria, proteinuria, and renal
failure. Defining the link between the molecular defect and the
progression of the disease remains a challenging problem.
Maybe the disease, as opposed to the membrane defect, is
produced by secondary changes that take a long time to
develop. Of course, this hypothesis offers us the hope that, if
we can find out what the secondary changes are, we might
prevent them from occurring, even if we can't repair the
underlying mutation. I think that we're going to learn that
cloning the gene isn't the whole story. In Alport's syndrome,
for example, we need to know how the basement membrane
works before we can adequately interpret the effects of the
mutations.
DR. FREDRIC 0. FLNKELSTEIN (Clinical Professor of Medi-
cine, Yale University School of Medicine, and Chief of
Nephrology, St. Raphael's Hospital, New Haven, Connecti-
cut): As in the first case, interstitial changes often are a
prominent feature of the histology of Alport's syndrome. How
do you explain those changes on the basis of the genetic
analysis?
DR. REEDERS: Perhaps I should refer that question to Dr.
Kashgarian.
DR. KASHGARIAN: Two possibilities could account for the
histologic alterations. One is that the primary glomerular le-
sions result in sclerosis with secondary tubular changes. The
second possibility relates to the hypothetical pathogenesis that
Dr. Reeders just mentioned. Imagine that the factor triggering
the development of the clinical entity, Alport's syndrome, is an
independent, primary renal disease that would resolve in a
normal individual and not be clinically evident, but that, in an
affected individual, it stimulates collagen production and results
in an imbalance in the relative amounts of various chains and
thus in an abnormal basement membrane. The abnormal base-
ment membrane then might stimulate cytokine production by
mesangial cells, epithelial cells, and endothelial cells. The
filtered cytokines and growth factors could initiate interstitial
fibrosis. I believe that any alterations that occur in the glomer-
ulus can affect the tubules and interstitium downstream from it.
DR. REEDERS: I think interstitial fibrosis is unlikely to be a
direct effect because, at least as far as we know, a5(IV) is not
expressed in the tubules.
DR. GARY DESIR (Assistant Professor of Medicine, Yale
University School of Medicine): Is the evidence for saying that
a3(IV) and a4(IV) are absent from basement membrane in
Alport's syndrome solely based on immunologic studies, or are
protein sequence data available for the collagens in patients
with Alport's syndrome? Is it possible that a3(IV) and a4(IV)
actually are present in the basement membrane but do not react
to the antibodies?
DR. REEDERS: No one has been able to sequence peptides
obtained from GBM samples from patients with Alport's syn-
drome. The best evidence to date comes from a single report
from Kleppel's group demonstrating the absence of silver
staining of electrophoresed NC 1 components from 2 patients
with Alport's syndrome [231. Except for Kleppel's report, all
the other evidence is immunologic: antibodies that react with
a3(IV) and a4(IV) in normal tissue do not react with Alport's
syndrome membranes. Kleppel's work is critical. If it holds up,
the most likely situation is that the a3(IV) and a4(IV) chains are
not in GBM to any significant extent.
DR. JOHN P. HAYSLETT (Professor of Medicine, Yale Uni-
versity School of Medicine): Other genetic diseases are associ-
ated with glomerular injury. Two that come to mind are
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nail-patella syndrome and retinal degeneration. Is it known
whether these entities involve alterations in type IV collagens
and glomerular basement membrane?
Da. REEDERS: It's not known to me. Does any one else know
of studies in these diseases?
DR. GREGORY G. GERMINO (Assistant Professor of Medicine,
Yale University School of Medicine): Linkage has been found to
the ABO blood group on chromosome 9 in at least some of the
families with nail-patella syndrome [32—34]. I don't think any
type IV collagens have been mapped to chromosome 9.
DR. REEDERS: That's right. I don't know of any immuno-
chemical studies of the basement membrane in these syn-
dromes.
DR. KASHGARIAN: In nail-patella syndrome, the anatomic
finding is the presence of fibrillar collagen, which resembles
type III fibrillar collagen in the basement membranes. In
nail-patella syndrome, at least morphologically, it appears that
a non-basement-membrane collagen is being incorporated. I
don't know how that relates to the genetics.
DR. REEDERS: The presence of fibrillar collagen again could
be a secondary effect, because invasion of the GBM by other
collagens occurs in other diseases, such as diabetic nephrop-
athy.
DR. MARGARET J. Bi (Professor of Medicine and Director of
Transplant Nephrology, Yale University School of Medicine):
Some transplant centers have found that most of their patients
with Alport's syndrome do not develop anti-GBM antibodies,
nor do these patients develop rapidly progressive glomerulone-
phritis after transplantation [35]. Can you explain why only
some patients develop anti-GBM antibodies post-transplant and
others do not?
DR. REEDERS: The immune systems of males in whom a5(IV)
is not stably incorporated into basement membrane have not
been exposed to a5(IV), at least in a normal configuration
within the "chicken-wire" superstructure of the GBM. When a
kidney containing a5(IV) is transplanted, these males should
react to it. One would expect that most Alport's syndrome
mutations are going to cause failure of stable incorporation of
a5(IV) in GBM, so one might expect most individuals to
generate anti-GBM antibodies. At the recent International
Workshop, Kashtan reported preliminary evidence of a corre-
lation between a5(IV) deletions and the development of anti-
GBM antibodies. However, Dr. Martin Bobrow reported that 2
patients treated at Guy's Hospital, London, had extensive
deletions of the NC 1 domain of a5(IV), and yet neither patient
developed anti-GBM disease after heterologous transplanta-
tion. Bobrow's data have not yet been published. Perhaps a
trivial explanation exists for the pattern of anti-GBM disease.
Because transplant recipients are heavily immunosuppressed to
prevent rejection, perhaps a coincidental benefit is suppression
of anti-GBM disease. Is that reasonable?
DR. BIA: I'm not sure, because the amount of immunosup-
pression used in renal transplant patients is fairly standardized,
at least in this country. Furthermore, much of the immunosup-
pression utilized, like high doses of methylprednisolone, is not
that effective in treating anti-GBM disease, so I'm not sure I
agree with you.
DR. REEDERS: That's fair enough. I'm not sure about it
myself.
DR. GERMIN0: Do you know of any histologic or immunoflu-
orescence data on the autosomal forms of Alport's syndrome?
Do these patients have the characteristic basket-weave pattern,
absence of the Goodpasture's antigen, or any other character-
istic features?
DR. REEDERS: The problem is that the autosomal form of
Alport's syndrome is not well recognized. The consensus has
swung from the 1950s, when autosomal dominant inheritance
was considered common, to the belief in the 1980s that all
Alport's syndrome mutations are X-linked. We now have to
shift back to the belief that some are autosomal dominant. Some
studies might be tainted by cross-contamination of the two
genetic groups, especially because the mode of inheritance
often is hard to determine in small families. As far as I know,
several of the families presumed to have autosomal transmis-
sion have thinning of the GBM as the major finding, but no
systematic studies are available. It may be that GBM thinning is
more common in patients with autosomal mutations. We don't
know whether the GBMs in autosomal cases stain with Good-
pasture's antibody.
DR. KASHGARIAN: You just raised this question: what is the
relationship of thin-basement-membrane disease to Alport's
syndrome?
DR. REEDERS: I suspect that some mutations in type IV
collagen produce thin basement membranes. Some patients in
this category develop renal failure; some don't. Other muta-
tions produce the whole range of changes associated with
Alport's syndrome. Depending on the nature of the mutation
and other factors that contribute to the progression of the
disease, there can be progression from thinning of the GBM to
GBM splitting in some cases. If these kidneys were to be
sampled at a critical time, one might expect to see the two types
of pathology in the same kidney. I think thin-basement-mem-
brane disease and Alport's syndrome are variants of the same
disease. What do you think?
DR. KASHGARIAN: I think they probably are.
DR. COHEN: May we return to the kindred that seemed to
evidence male-to-male transmission (Fig. 2)? Do we know the
mother's pedigree? Could she have been a carrier who just
happened to marry someone who also had the gene?
DR. REEDERS: That's a very good question. When male-to-male
transmission is observed, the possibility always exists that it isn't
true male-to-male transmission but female-to-male transmission
from the other side of the family. In other words, the affected son
was unlucky enough to have both a father and a mother with the
disease. That instance should be very rare because Alport's
syndrome is in itself a rare disease. Of course, intermarriage is not
uncommon in some populations, and it wouldn't be surprising to
see an occasional case of this type. Dr. Antignac in Paris just
reported a family in which a case of male-to-male transmission
was likely, yet X-linkage also was demonstrated by genetic
linkage analysis. It turned out that the mother of the affected boy
also was affected, although the disease was essentially silent in
her, and that the boy's parents were closely related. One must be
very careful in interpreting family data. It is important to exclude
X-linkage before putting a big investment into studying a family
with autosomal markers. Genetic linkage analysis has been done
in several such families and X-linkage has been excluded. In many
other families that have been reported, one cannot entirely ex-
clude the possibility that the putative male-to-male transmission is
merely apparent rather than real.
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Note added in proof
A new article by Hudson et al [361 presents data indicating that the a3
(IV) chain in type IV collagen molecules is the target Alport alloantigen
and that the epitope(s) reside in the NC1 domain of this chain. These
authors also report that the Alport alloantigen is identical to the
Goodpasture autoantigen, the a3 (IV) chain.
Reprint requests to Dr. S. Reeders, Yale University School of
Medicine, 295 Congress Avenue, P. 0. Box 9812, New Haven, Con-
necticut, 06536-0812, USA
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